How to Invest in Cardiovascular Disease Treatments
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Your trusted source for investing success
Your trusted source for investing success
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and
By Jocelyn Aspa
Mitel (NASDAQ:MITL; TSX:MNW) has announced the recognition of Frontier Communications (NASDAQ:FTR) as its leading US partner in 2016 and for the sixth consecutive year.
As quoted in the press release:
Frontier also received Mitel’s Top U.S. Service Provider award.
As a Mitel-Authorized Partner for 27 years, Frontier provides Mitel solutions to business customers
Investing in the medical device sector might be intimidating, but the Investing News Network outlines why it is worth your while.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of
Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA’s ASD-002, which is being developed to treat a rare pediatric nonverbal disorder.
Through their multiple holdings, ETFs provide immediate diversification to buyers. That’s particularly important in the medical device market.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New
We take a look at the latest medical device companies that received an FDA clearance, what their products are about and their stock performance.
BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration
Who are the top performing ETFs in the pharmaceuticals, biotechnology and life sciences markets year-to-date?
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based biotechs are entering this space.
By Pia Rivera
Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).
As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on
St. Jude Medical shareholders approved the merger agreement under which Abbott (NYSE:ABT) will acquire St. Jude Medical.
We touched base with Greg Cash, CEO of BioSig Technologies, to hear his thoughts on the state of the market and what investors might expect going forward.
The company warns that built up lithium deposits in their defibrillators’ batteries can cause them to short circuit.
In the high risk realm of pharmaceutical investing, stocks that pay dividends can seem more secure: here are companies confident and established enough to regularly share corporate profits among shareholders.
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company with a glaucoma drug in development through its partner Mannin Research provides this update on the MAN-01 program and its relevance in the glaucoma market.
Johnson & Johnson is warning customers that its Animas OneTouch Ping Insulin pump can be hacked—a cybersecurity vulnerability that could be deadly.
Despite some industry hurdles, several pharmaceutical companies have managed to come out ahead—and so have their shareholders.
